Donate
GALA
New Family
The Dup15q Alliance is aware of the recent release by the FDA regarding Keppra, Keppra XR, Elepsia XR, Spritam (levetiracetam) and Onfi, Sympazan (clobazam) warning about the risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). This adverse event is rare and generally occurs 2-8 weeks after starting a medication. We urge anyone with concerns about their medications to discuss with their prescribing provider. The FDA recommends not stopping these medications without discussing with your health care provider, as stopping these medications suddenly can lead to uncontrolled seizures.
FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and clobazam (Onfi, Sympazan) | FDA

Related Posts

SOAR Webinar

SOAR Webinar

by | Apr 18, 2025

**At this time, the SOAR study has reached capacity for conference participation. However, there still may be opportunities for research participation at the family conference due to cancellations or addition of other opportunities. If you would like to be placed on a...

FDA Issues Recall On Clonazepam Orally Disintegrating Tablets

FDA Issues Recall On Clonazepam Orally Disintegrating Tablets

by | Dec 2, 2024

The Dup15q Alliance is aware of the recent release by the FDA regarding Clonazepam Orally Disintegrating Tablets USP by Endo USA due to potential product carton strength mislabeling. Ongoing investigation identified the possibility that the affected clonazepam product...

Recall – Vigabatrin for Oral Solution USP

Recall – Vigabatrin for Oral Solution USP

by | Dec 12, 2023

TOPIC: Vigabatrin for Oral Solution USP, 500 mg by InvaGen Pharmaceuticals: Recall - Due to Leaking Sachets AUDIENCE: Patient, Health Professional, Pharmacy, Pediatric, Neurology ISSUE: InvaGen Pharmaceuticals is recalling one lot, NB301030, of Vigabatrin for Oral...